The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) incorporates p53 expression as a surrogate for TP53 mutations, representing the copy-number high group [12,15,16,17]. This evidence concerns the gene TP53 and endometrial cancer.